Reversibility of capillary density after discontinuation of bevacizumab treatment

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1100-1105

  Steeghs, N ^a   Rabelink, T J ^b   Op 't Roodt, J ^b   Batman, E ^c   Cluitmans, F H M ^d   Weijl, N I ^a,e   de Koning, E ^b   Gelderblom, H ^a  

^a Department of Clinical Oncology ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Deaconess Hospital   (Netherlands)

^d RIJNLAND HOSPITAL   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Angiogenesis; Bevacizumab; Capillary density; Hypertension; Rarefaction; Vascular endothelial growth factor inhibitor

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; IRINOTECAN; LOOP DIURETIC AGENT; OXALIPLATIN; PACLITAXEL; THIAZIDE DIURETIC AGENT; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CAPILLARY DENSITY; CAPILLARY FLOW; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PULSE WAVE; TREATMENT OUTCOME; VASODILATATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; BREAST NEOPLASMS; CAPILLARIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIP; MALE; MICROCIRCULATION; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953354537     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp417     Document Type: Article

References (22)

1. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
2. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
3. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
4. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
5. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
6. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
7. Steeghs N, Gelderblom H, Roodt JO et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14: 3470-3476.
8. Mourad JJ, des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927-934.
9. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
10. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006; 5: 553-566.
11. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795.
12. Kapiteijn E, Brand A, Kroep J et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18: 1745-1747.
13. Groner W, Winkelman JW, Harris AG et al. Orthogonal polarization spectral imaging: a new method for study of the microcirculation. Nat Med 1999; 5: 1209-1212.
14. Ince C. The microcirculation is the motor of sepsis. Crit Care 2005; 9 (Suppl 4): S13-S19.
15. Van Bortel LM, Balkestein EJ, van Der Heijden-Spek JJ et al. Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. J Hypertens 2001; 19: 1037-1044.
16. Kamba T, Tam BY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290: H560-H576.
17. Baffert F, Le T, Sennino B et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290: H547-H559.
18. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
19. Bono P, Elfving H, Utriainen T et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009; 20: 393-394.
20. Rini BI, Schiller JH, Fruehauf JP et al. Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 2008; 26 (Suppl): (Abstr 3543).
21. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007; 18: 1117.
22. Friberg G, Kasza K, Vokes EE et al. Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with bevacizumab and gemcitabine. J Clin Oncol 2005; 23 (Suppl): (Abstr 3020).